Assessment of Health Related Quality of Life in Women Who Underwent Breast Reconstruction After Radical Surgery (RMQOL)

June 23, 2021 updated by: Centre Georges Francois Leclerc

Assessment of Health Related Quality of Life in Women Who Underwent Breast Reconstruction After Radical Surgery (RMQOL)

Nowadays, breast reconstruction is an integral care after mastectomy in breast cancer patient.

With the personalized care, choice a breast reconstructive is an important step involving decisions and mutual accord between patients and their physicians in order to anticipate clinical and psychosocial results.

Two main families of breast reconstruction techniques are often performed including advantages and complications impacting health related quality of life.

Routine assessment of health related quality of life in patients underwent breast reconstruction could allow to identify factors of satisfaction o be taken into account in the choice of breast reconstruction technique in order to improve practices and quality of life of patients

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Dijon, France
        • Recruiting
        • Centre Georges François Leclerc
        • Contact:
        • Principal Investigator:
          • Clémentine JANKOWSKI, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patient undergoing breast reconstruction after mastectomy for breast cancer

Description

Inclusion Criteria:

  • Normal Breast Checkup ( Mammography, echography and breast magnetic resonance imaging)in the previous 6 months
  • French speaking and writing fluency
  • Agree to participate after receive all information

Exclusion Criteria:

  • Patients with an inability to complete HRQOL questionnaires (cognitive disorders, language barrier)
  • Patient with a failed first breast reconstruction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Health related quality of life scores assessed by Breast Q questionnaire
Time Frame: 12 months after breast reconstruction
12 months after breast reconstruction

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of anxious and depress participants as assessed by Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 months after breast reconstruction
HADS has 14 items rated from 0 to 3 and covers 2 dimensions. Seven questions related to the anxiety dimension and seven other related to the depressive dimension, yielding 2 scores, A (Anxiety) and D (Depression). The maximum score for each dimension is 21. A score of 11 or higher indicates the probable presence of the disorder.
12 months after breast reconstruction
social support as assessed by Sarason's Social Support Questionnaire 6-item (SSQ6)
Time Frame: 12 months after breast reconstruction
Social support is measured across 2 dimensions: support availability, through the number of contacts that the patient can count on (0 to 9 people) and quality of support, through patient satisfaction with support received. Each item represents a situation in which the patient may need support. Patient is asked to cite the number of people that she could count on in that particular situation. Concerning the second item, the patient is asked to assess satisfaction with the support provided. The scores are generated according to Sarason's recommendations. A score is calculated for each dimension. Support availability score is calculated as the sum of the number of people available for the 6 items, this score ranges from 0 to 54, with 54 representing the highest availability. The social support satisfaction score is calculated by the sum of the satisfaction of the 6 items. This score ranges from 6 to 36, with 36 representing the highest level of satisfaction
12 months after breast reconstruction
level of the precariousness and the disparities of health at breast reconstruction patient by the questionnaire Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health (EPICES)
Time Frame: 12 months after breast reconstruction
EPICES is used to assess individual level of the precariousness. It includes 11 items and generate precariousness score from 0 to 100. Patient which a score EPICES >30 is considered as having a high level of precariousness
12 months after breast reconstruction
Health related quality of life scores assessed by Breast Q questionnaire
Time Frame: 24 months after breast reconstruction
24 months after breast reconstruction
Health related quality of life scores assessed by Breast Q questionnaire
Time Frame: 36 months after breast reconstruction
36 months after breast reconstruction
Health related quality of life scores assessed by Breast Q questionnaire
Time Frame: 48 months after breast reconstruction
48 months after breast reconstruction
Health related quality of life scores assessed by Breast Q questionnaire
Time Frame: 60 months after breast reconstruction
60 months after breast reconstruction

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Clementine JANKOWSKI, MD, Centre Georges François Leclerc

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2019

Primary Completion (Anticipated)

May 4, 2024

Study Completion (Anticipated)

May 4, 2025

Study Registration Dates

First Submitted

June 16, 2021

First Submitted That Met QC Criteria

June 23, 2021

First Posted (Actual)

June 24, 2021

Study Record Updates

Last Update Posted (Actual)

June 24, 2021

Last Update Submitted That Met QC Criteria

June 23, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2018-A011828-47

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

3
Subscribe